• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
Right Arrow Button IconLeft Arrow Button IconHome
Right Arrow Button IconWegovy

Wegovy

Page 2 of 6
The increase in online searches for obesity management drugs in recent years correlated to a surge in dispensed prescriptions, according to a new study from the Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease.
HealthOnline searches predicted the surge in prescriptions of weight-loss drugs like Wegovy and Zepbound, study says. Here’s what could happen next
By Lindsey LeakeJanuary 29, 2025
A person, with only the midsection visible, injects Wegovy under the skin of their stomach.
FinanceNovo Nordisk stock surges 7% after Ozempic maker’s latest weight-loss drug shows promise
By Greg McKennaJanuary 24, 2025
Eli Lilly & Co., the Fortune 500 pharma firm that manufactures weight-loss injection Zepbound (tirzepatide), has a comparable oral medication in the works that could be approved by the FDA as early as 2026, CEO Dave Ricks told Bloomberg TV on Jan. 13, 2025.
HealthHate needles? Lilly’s weight-loss pill could get FDA approval next year, CEO says
By Lindsey LeakeJanuary 21, 2025
Elon Musk admits he takes an Ozempic-like weight-loss drug that RFK Jr. wants to restrict
HealthElon Musk admits he takes an Ozempic-like weight-loss drug that RFK Jr. wants to restrict
By Alexa MikhailDecember 27, 2024
Novo Nordisk advertising flags and logo on facade, Danish pharmaceutical healthcare giant Novo Nordisk AS, production innovative drugs, obesity treatment Ozempic, Mainz, Germany June 15, 2024
HealthNovo Nordisk faces stock market bloodbath after weight-loss drug trial disappoints
By Ryan Hogg and AFPDecember 20, 2024
Merck snags Chinese obesity drug in nearly $2 billion deal
TechMerck snags Chinese obesity drug in nearly $2 billion deal
By Robert Langreth and BloombergDecember 18, 2024
Novo Nordisk invests $1.2 billion in new Danish factory to expand beyond insulin and weight-loss
TechNovo Nordisk invests $1.2 billion in new Danish factory to expand beyond insulin and weight-loss
By AFPDecember 16, 2024
Close-up of a patient administering a dose of Zepbound (tirzepatide)
HealthZepbound vs. Wegovy: New clinical trial says this weight-loss medication sheds more pounds
By Lindsey LeakeDecember 4, 2024
Biden proposes Medicare and Medicaid cover weight-loss drugs like Wegovy and Ozempic for millions of obese Americans
HealthBiden proposes Medicare and Medicaid cover weight-loss drugs like Wegovy and Ozempic for millions of obese Americans
By Amanda Seitz and The Associated PressNovember 26, 2024
High demand for weight loss drugs like Ozempic and Wegovy is impacting employer health care costs—but it can be critical for retaining talent
LeadershipHigh demand for weight loss drugs like Ozempic and Wegovy is impacting employer health care costs—but it can be critical for retaining talent
By Brit MorseNovember 21, 2024
Novo Nordisk launches Wegovy in China with prices well below U.S.
HealthNovo Nordisk launches Wegovy in China with prices well below U.S.
By Amber Tong and BloombergNovember 18, 2024
Novo Nordisk’s Wegovy sales jump on international rollouts
RetailNovo Nordisk’s Wegovy sales jump on international rollouts
By Naomi Kresge and BloombergNovember 6, 2024
Drugs like Ozempic and Wegovy are linked to a lower risk of Alzheimer’s disease, new study says
HealthDrugs like Ozempic and Wegovy are linked to a lower risk of Alzheimer’s disease, new study says
By Ani FreedmanOctober 24, 2024
Ozempic and Wegovy are trimming waistlines—and showing how quickly U.S. health care can turn into a gold rush
CommentaryOzempic and Wegovy are trimming waistlines—and showing how quickly U.S. health care can turn into a gold rush
By Owen TrippOctober 23, 2024
Companies are more willing to consider covering weight-loss drugs
HealthCompanies are more willing to consider covering weight-loss drugs
By Chris MorrisOctober 10, 2024
1
  • 1
  • 2
  • 3
  • 4
  • 5
6
Most Popular
AI
A Meta employee created a dashboard so coworkers can compete to be the company's No. 1 AI token user—and Zuckerberg doesn't even rank in the top 250placeholder alt text
By Fortune EditorsApril 9, 2026
Economy
The U.S. government is spending $88 billion a month in interest on national debt—equal to spending on defense and education combinedplaceholder alt text
By Fortune EditorsApril 9, 2026
Investing
Mark Cuban admits he made a mistake letting go of the Mavericks: 'I don't regret selling. I regret who I sold to'placeholder alt text
By Fortune EditorsApril 9, 2026
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.